How to buy Novo Nordisk A/S stock

Novo Nordisk A/S is a biotechnology business based in the US. Novo Nordisk A/S shares (NVO) are listed on the NYSE and all prices are listed in US Dollars. Novo Nordisk A/S employs 50,816 staff and has a trailing 12-month revenue of around $157.3 billion.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Novo Nordisk A/S stock price (NYSE: NVO)

Use our graph to track the performance of NVO stocks over time.

Novo Nordisk A/S shares at a glance

• Key figures

Information last updated 2022-10-02.

Latest market close	$99.63
52-week range	$90.40 - $121.50
50-day moving average more info button	$105.89
200-day moving average more info button	$107.13
Wall St. target price	$126.42
PE ratio more info button	34.5937
Dividend yield more info button	$11.15 (1.61%)
Earnings per share (TTM) more info button	$2.88

Buy Novo Nordisk A/S shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Novo Nordisk A/S stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Novo Nordisk A/S price performance over time

Historical closes compared with the close of $99.63 from 2022-09-30

1 week (2022-09-27)	3.89%
1 month (2022-09-02)	-2.55%
3 months (2022-07-01)	-10.76%
6 months (2022-04-04)	-12.46%

1 year (2021-10-04)	2.77%
2 years (2020-10-02)	45.11%
3 years (2019-10-04)	94.13%
5 years (2017-10-04)	102.17%

Is Novo Nordisk A/S stock undervalued or overvalued?

Valuing Novo Nordisk A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novo Nordisk A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Novo Nordisk A/S's P/E ratio

Novo Nordisk A/S's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Novo Nordisk A/S shares trade at around 35x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Novo Nordisk A/S's PEG ratio

Novo Nordisk A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7345. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novo Nordisk A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Novo Nordisk A/S's EBITDA

Novo Nordisk A/S's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $72 billion.

The EBITDA is a measure of a Novo Nordisk A/S's overall financial performance and is widely used to measure a its profitability.

Novo Nordisk A/S financials

Revenue TTM	$157.3 billion
Operating margin TTM	42.68%
Gross profit TTM	$117.1 billion
Return on assets TTM	22.25%
Return on equity TTM	72.19%
Profit margin	32.14%
Book value	$32.81
Market capitalisation more info button	$225.4 billion

TTM: trailing 12 months

Novo Nordisk A/S share dividends

Dividend payout ratio: 7.24% of net profits

Recently Novo Nordisk A/S has paid out, on average, around 7.24% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.61% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novo Nordisk A/S shareholders could enjoy a 1.61% return on their shares, in the form of dividend payments. In Novo Nordisk A/S's case, that would currently equate to about $11.15 per share.

While Novo Nordisk A/S's payout ratio might seem low, this can signify that Novo Nordisk A/S is investing more in its future growth.

Novo Nordisk A/S's most recent dividend payout was on 22 August 2022. The latest dividend was paid out to all shareholders who bought their shares by 11 August 2022 (the "ex-dividend date").

Have Novo Nordisk A/S's shares ever split?

Novo Nordisk A/S's shares were split on a 5:1 basis on 8 January 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk A/S shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Novo Nordisk A/S shares which in turn could have impacted Novo Nordisk A/S's share price.

Novo Nordisk A/S share price volatility

Over the last 12 months, Novo Nordisk A/S's shares have ranged in value from as little as $90.4 up to $121.5047. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novo Nordisk A/S's is 0.2894. This would suggest that Novo Nordisk A/S's shares are less volatile than average (for this exchange).

Novo Nordisk A/S overview

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease.

Frequently asked questions

What percentage of Novo Nordisk A/S is owned by insiders or institutions?
Currently 0.007% of Novo Nordisk A/S shares are held by insiders and 8.671% by institutions. How many people work for Novo Nordisk A/S?
Latest data suggests 50,816 work at Novo Nordisk A/S. When does the fiscal year end for Novo Nordisk A/S?
Novo Nordisk A/S's fiscal year ends in December. Where is Novo Nordisk A/S based?
Novo Nordisk A/S's address is: Novo Allé 1, Bagsvaerd, Denmark, 2880 What is Novo Nordisk A/S's ISIN number?
Novo Nordisk A/S's international securities identification number is: US6701002056 What is Novo Nordisk A/S's CUSIP number?
Novo Nordisk A/S's Committee on Uniform Securities Identification Procedures number is: 670100205